Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
5.45
-0.01 (-0.18%)
At close: Apr 28, 2026, 4:00 PM EDT
5.20
-0.25 (-4.59%)
After-hours: Apr 28, 2026, 4:30 PM EDT
Quoin Pharmaceuticals Employees
As of December 31, 2024, Quoin Pharmaceuticals had 5 total employees, including 3 full-time and 2 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,160,931
Market Cap
9.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| CytoMed Therapeutics | 43 |
| Lunai Bioworks | 29 |
| Imunon | 25 |
| BioLineRx | 24 |
| Kiora Pharmaceuticals | 13 |
| Genprex | 13 |
| BioVie | 13 |
QNRX News
- 7 hours ago - CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - GlobeNewsWire
- 10 hours ago - Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - GlobeNewsWire
- 4 weeks ago - Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome - GlobeNewsWire
- 5 weeks ago - Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - GlobeNewsWire
- 6 weeks ago - Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - GlobeNewsWire
- 3 months ago - Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - GlobeNewsWire
- 3 months ago - Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome - GlobeNewsWire
- 6 months ago - Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - GlobeNewsWire